From the Journals

ICYMI: Alpelisib/fulvestrant combo boosts PFS in advanced breast cancer


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer who had previously undergone endocrine therapy experienced longer progression-free survival when receiving alpelisib and fulvestrant, compared with placebo and fulvestrant (11.0 vs. 5.7 months; hazard ratio, 0.65; 95% confidence interval, 0.50-0.85; P less than .001), according to a randomized, phase 3 trial published in the New England Journal of Medicine (2019 May 15. doi: 10.1056/NEJMoa1813904).

We first reported on the results of this trial when they were presented at the European Society for Medical Oncology Congress. Find our coverage at the link below.

Next Article: